Takeda is launching a restructuring, targeting nearly $1.3 billion in annual savings. Generic versions of Novo Nordisk's ...
While Lilly’s position in the obesity market and wider GLP-1 space has remained largely unshakeable in recent months, a | ...
In its 100th year in operation, family-run Recordati is considering a buyout offer from CVC Capital Partners. | CVC Capital ...
Roche’s Genentech is backing this year’s Walk to End Lupus Now, taking up a sponsorship opportunity claimed by GSK in ...
With key expansions coming to fruition on either side of the pond, specialist CDMO Hovione is making sure that drugmakers can ...
Addressing pressing questions about upcoming ATTR-CM competition and market opportunity, Alnylam management on Tuesday ...
After becoming a prominent public face of the CDC’s revamped Advisory Committee on Immunization Practices (ACIP), physician ...
New drug manufacturer Neion Bio has emerged from stealth after incubating a novel way to cook up biologic drugs. | The new ...
After attracting GSK with its subcutaneous delivery tech at the top of the year, South Korea’s Alteogen has snared another ...
Corcept's lead drug bounces back from FDA snub with different approval as Lifyorli in ovarian cancer
The FDA has given the all-clear to Corcept’s class-first Lifyorli (relacorilant) to treat adults with platinum-resistant ...
UCB plans to build a $2 billion manufacturing facility near its U.S. headquarters in Atlanta, Georgia. It will become the ...
Ionis Pharmaceuticals is dramatically lowering the price of its blockbuster hopeful Tryngolza (olezarsen) as it prepares to ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results